Joel Greenblatt’s MacroGenics MGNX Stock Holding History

Joel Greenblatt’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,347	Closed	-$330K	–	1057
2021 Q1	$330K	Buy	+10,347	New	+$251K	0.01%	807
2018 Q2	–	Sell	-10,409	Closed	-$262K	–	974
2018 Q1	$262K	Buy	+10,409	New	+$253K	﹤0.01%	844
2015 Q3	–	Sell	-32,087	Closed	-$1.22M	–	989
2015 Q2	$1.22M	Buy	+32,087	New	+$1.05M	0.01%	603

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Joel Greenblatt's MGNX Position: Q2 2021 in Review

Joel Greenblatt sold out of MacroGenics (MGNX) in Q2 2021, closing a stake of 10,347 shares — an estimated $330K sold.

Joel Greenblatt first reported a position in MGNX in Q2 2015 and held it in 3 quarters. The position peaked at $1.22M in Q2 2015. 149 funds tracked by Wall St. Rank hold MGNX as of Q2 2021.

Joel Greenblatt reported no remaining MacroGenics position as of Q2 2021 after selling out during the quarter.
Joel Greenblatt sold 10,347 MacroGenics shares in Q2 2021, an estimated $330K.
Joel Greenblatt first reported a position in MacroGenics in Q2 2015 and held it in 3 quarters.
Joel Greenblatt's MacroGenics position peaked at $1.22M in Q2 2015.
149 funds tracked by Wall St. Rank held MacroGenics as of Q2 2021.

Based on Gotham Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.